Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder mediated by pathogenic autoantibodies. Although modern medicine offers effective short-term symptom control, its long-term treatment is limited by adverse drug reactions, complications, and disease recurrence. Integrated traditional Chinese and western medicine (ICWM) has demonstrated potential advantages in the immunomodulatory treatment of MG. Various traditional Chinese medicine (TCM) monomers and compound prescriptions exert therapeutic effects through multiple mechanisms, including suppression of autoantibody production, regulation of cellular immune imbalance, inhibition of complement activation, and modulation of cytokine networks and signaling pathways. These actions help restore neuromuscular junction function and alleviating MG symptoms. Furthermore, combining TCM with conventional therapies may help reduce adverse reactions, enhance remission rates, and improve the patients' quality of life. This also provides new insights into personalized treatment strategies. However, current experimental and clinical research on ICWM for MG still requires further refinement and standardization to meet higher scientific rigor.